Study how targeted drugs affect bone tumors in lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies how tyrosine kinase inhibitor (TKI) medicines work against non-small cell lung cancer that has spread to the bone. It’s for people with specific “actionable” gene changes, to see how well these treatments reduce or change bone metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign the consent form and agree to follow study visits and procedures
- You’re 18 to 100 years old and have non-small cell lung cancer confirmed by testing
- Your tumor (or blood) must be tested with a validated DNA test to find the actionable gene mutation
- Your general health activity level is ECOG 0 to 2 (roughly: fully active to limited but able to care for yourself)
- A doctor has already chosen your usual lung cancer treatment plan (TKI and/or chemotherapy, with or without immunotherapy)
- Your lung cancer has spread to the bone and this must be seen on imaging before joining
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medication (JMT103) for people with giant cell tumor of bone that cannot be safely removed with surgery. The drug may help shrink the tumor or slow its growth, providing an option when surgery is too risky.
This trial tests a new medicine (JMT103) against a standard treatment (zoledronic acid) to see if it is better at preventing bone complications like fractures, pain, or needing radiation or surgery on the bones. It is for people whose cancer has spread to their bones.
This Phase 2 trial tests ZEN003694 in people with squamous (a type of) lung cancer that has returned or spread. It’s designed for tumors that have a certain gene change, and it may offer a new treatment option after prior chemotherapy and immunotherapy.
This study tests whether zoledronic acid, a medicine given by IV, helps prevent bone problems in women with breast cancer that has spread to the bones. It looks at how well the drug works in a real-world setting to reduce the risk of fractures or other bone issues.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), a bone-strengthening drug (denosumab), and chemotherapy for people with advanced or spread non-squamous non-small cell lung cancer that does not have certain genetic changes. The goal is to see if this combination helps shrink tumors and control the disease.
This trial tests a new drug called zongertinib combined with chemotherapy, with or without pembrolizumab (an immunotherapy), for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. The goal is to see how safe and well-tolerated the combination is.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.